Table 1.
Overall survival analysis (n = 155).
| OS, n = 155 Variables (n) |
Kaplan—Meier Survival Analysis | UNIVARIATE Cox Regression | MULTIVARIATE Cox Regression | ||||
|---|---|---|---|---|---|---|---|
| X2 | p-Value | OS (Range) | HR (IC 95%) | p-Value | HR (IC 95%) | p-Value | |
| Age ≥ 65years (vs. <65 years) | 0.9 | 0.343 | 67.5 (58.9–76.1) vs. 78.0 (65.9–90.1) | 1.6 (0.8–3.1) | 0.171 | - | - |
| FIGO stage III (vs. stage I–II) | 2.1 | 0.150 | 72.9 (67.4–78.4) vs. 78.0 (66.8–89.3) | 1.6 (0.8–2.9) | 0.153 | - | - |
| Tumor grade 3 (vs. grade 1–2) | 2.1 | 0.145 | 67.6 (61.1–74.1) vs. 85.7 (75.6–95.9) | 1.6 (0.8–3.3) | 0.210 | - | - |
| Endometrioid histology (vs. other histology) | 0.0 | 0.869 | 80.3 (71.2–89.4) vs. 69.5 (61.6–77.5) | 0.9 (0.4–1.7) | 0.656 | - | - |
| NLR ≥ 2.2 (vs. <2.2) |
4.8 | 0.028 | 66.4 (59.6–73.2) vs. 91.7 (82.5–100.9) | 2.2 (1.1–4.7) | 0.043 | 2.3 (1.1–4.6) | 0.027 |
| SII ≥ 1100 (vs. <1100) |
5.6 | 0.017 | 58.5 (44.9–72.1) vs. 82.3 (73.5–91.2) | 2.2 (1.1–4.6) | 0.047 | 2.3 (1.2–4.7) | 0.017 |
| MLR ≥ 0.18 (vs. <0.18) |
7.1 | 0.008 | 75.4 (67.2–83.6) vs. 79.4 (74.7–84.1) | 5.0 (1.1–20.8) | 0.027 | 5.9 (1.4–24.6) | 0.015 |
| Lymphocytes <1.0 (vs. ≥1.0) |
10.0 | 0.002 | 39.1 (21.6–56.6) vs. 82.1 (74.5–89.7) | 3.8 (1.6–9.0) | 0.003 | 4.3 (1.8–10.7) | 0.001 |
OS: overall survival, X2: Chi-square test, HR: Hazard Ratio, IC: confidence interval, FIGO: International Federation of Gynecology and Obstetrics, NLR: Neutrophil-to-Lymphocytes ratio, SII: Systemic Immune-Inflammatory Index, MLR: Monocyte-to-Lymphocyte ratio).